MARBOCYL 2 % W/V SOLUTION FOR INJECTION
Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Tabia za bidhaa
(SPC)
04-11-2016
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
MARBOFLOXACIN
Inapatikana kutoka:
Vetoquinol Ireland Limited
ATC kanuni:
QJ01MA93
INN (Jina la Kimataifa):
MARBOFLOXACIN
Kipimo:
2 %w/v
Dawa fomu:
Solution for Injection
Dawa ya aina:
POM
Kundi la matibabu:
Bovine, Porcine
Eneo la matibabu:
Marbofloxacin
Matibabu dalili:
Antibacterial
Idhini hali ya:
Authorised
Idhini ya tarehe:
1998-09-18
Tabia za bidhaa
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl 2% w/v Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
A yellow-greenish to yellow-brownish solution
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pre- ruminating and ruminating calves and pigs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In Calves
Marbofloxacin 2% is indicated in the treatment of respiratory infections caused by susceptible strains of organisms.
In Pigs
Marbofloxacin 2% is indicated in the treatment of respiratory infections caused by susceptible strains of organisms and in
the treatment of Metritis Mastitis Agalactia (MMA) syndrome caused by susceptible strains of organisms.
4.3 CONTRAINDICATIONS
Do not use in known cases of hypersensitivity to the active ingredient.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Each ml contains:
ACTIVE SUBSTANCE
Marbofloxacin
20.0 mg
EXCIPIENTS
Metacresol
2.0 mg
Monothioglycerol
0.5 mg
For a full list of excipients, see section 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 19/10/2016_
_CRN 7023455_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should
be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to
other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the
fluoroquinolone
Soma hati kamili
